Business Description
Shield Therapeutics PLC
ISIN : GB00BYV81293
Total Employee Number:
68Compare
Compare
Traded in other countries / regions
STX.UK1JS.GermanySHIEF.USA IPO Date
2016-03-07Description
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.39 | |||||
Equity-to-Asset | -0.23 | |||||
Debt-to-Equity | -2 | |||||
Debt-to-EBITDA | -3.53 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -5.07 | |||||
Beneish M-Score | -3.47 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 22.6 | |||||
3-Year EBITDA Growth Rate | 66.7 | |||||
3-Year EPS without NRI Growth Rate | 50.1 | |||||
3-Year FCF Growth Rate | 67.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 33.42 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.22 | |||||
9-Day RSI | 51.86 | |||||
14-Day RSI | 49.89 | |||||
3-1 Month Momentum % | -35.12 | |||||
6-1 Month Momentum % | -50.45 | |||||
12-1 Month Momentum % | 109.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.9 | |||||
Quick Ratio | 0.72 | |||||
Cash Ratio | 0.23 | |||||
Days Inventory | 100.33 | |||||
Days Sales Outstanding | 138.25 | |||||
Days Payable | 157.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -60.3 | |||||
Shareholder Yield % | -17.08 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 46.34 | |||||
Operating Margin % | -20.18 | |||||
Net Margin % | -35.47 | |||||
EBITDA Margin % | -17.3 | |||||
FCF Margin % | -7.45 | |||||
OCF Margin % | -6.81 | |||||
ROA % | -28.07 | |||||
ROIC % | -21.64 | |||||
3-Year ROIIC % | 128.28 | |||||
ROC (Joel Greenblatt) % | -3953.75 | |||||
ROCE % | -54.31 | |||||
Moat Score | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 8.18 | |||||
PS Ratio | 1.82 | |||||
EV-to-EBIT | -11.07 | |||||
EV-to-Forward-EBIT | 15.36 | |||||
EV-to-EBITDA | -12.51 | |||||
EV-to-Forward-EBITDA | 17.26 | |||||
EV-to-Revenue | 2.15 | |||||
EV-to-Forward-Revenue | 1.35 | |||||
EV-to-FCF | -30.73 | |||||
Price-to-GF-Value | 0.76 | |||||
Earnings Yield (Greenblatt) % | -9.02 | |||||
FCF Yield % | -4.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shield Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 42.724 | ||
| EPS (TTM) (€) | -0.018 | ||
| Beta | 2.9013 | ||
| 3-Year Sharpe Ratio | 0.54 | ||
| 3-Year Sortino Ratio | 1.06 | ||
| Volatility % | 108.51 | ||
| 14-Day RSI | 49.89 | ||
| 14-Day ATR (€) | 0.004489 | ||
| 20-Day SMA (€) | 0.067325 | ||
| 12-1 Month Momentum % | 109.62 | ||
| 52-Week Range (€) | 0.0245 - 0.152 | ||
| Shares Outstanding (Mil) | 1,069.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shield Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shield Therapeutics PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2025 | 2026-06-18 13:00 | 0.07 (+0.74%) | ||
| Annual report for 2025 | 2026-04-10 | 0.07 (-12.34%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-09 | 0.08 (-12.92%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 0.06 (-7.09%) | ||
| General meeting for 2024 | 2025-05-22 14:00 | 0.02 (+4.65%) | ||
| Annual report for 2024 | 2025-04-25 | 0.02 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-24 | 0.02 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-09-04 | 0.05 (+3.92%) |
Show
Entries
Shield Therapeutics PLC Frequently Asked Questions
What is Shield Therapeutics PLC(STU:1JS)'s stock price today?
The current price of STU:1JS is €0.07. The 52 week high of STU:1JS is €0.15 and 52 week low is €0.02.
When is next earnings date of Shield Therapeutics PLC(STU:1JS)?
The next earnings date of Shield Therapeutics PLC(STU:1JS) is 2026-08-21 Est..
Does Shield Therapeutics PLC(STU:1JS) pay dividends? If so, how much?
Shield Therapeutics PLC(STU:1JS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Shield Therapeutics PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers